Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04604509

Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial

Cigarette Smoking-Related Carcinoma Clinical Trial

Official title:
PISCES I: Precision Implemented Smoking Cessation Evaluation Study

Clinical Trial Summary

This phase IV trial investigates how to personalize treatments (such as medications and/or counseling) for quitting smoking based on the unique character traits of participants. Nicotine replacement therapy, counseling, and/or drugs such as varenicline and bupropion may help participants quit smoking or change smoking behavior. This trial may also help doctors individualize smoking cessation treatment for participants who do not quit smoking after the first course of treatment.

Clinical Trial Description

PRIMARY OBJECTIVES: I. Production of precise, unbiased estimates of treatment effects for the constituent therapies and rescue treatment pathways. II. Development of the predictive algorithm, using the same machine learning techniques described in the preliminary data, to estimate the probabilities that an individual with a given pattern of baseline covariates will successfully quit smoking at the six and twelve week time points. OUTLINE: STAGE I: Participants are randomized to 1 of 2 groups. GROUP I: Participants receive varenicline orally (PO) daily or twice daily (BID) for 6 weeks in the absence of unacceptable toxicity. Participants who quit smoking continue treatment for 6 additional weeks in the absence of unacceptable toxicity. Participants also receive behavioral smoking cessation counseling. GROUP II: Participants receive nicotine replacement therapy (NRT) consisting of a patch, lozenges, or gum daily for 6 weeks in the absence of unacceptable toxicity. Participants who quit smoking continue treatment for 6 additional weeks in the absence of unacceptable toxicity. Participants also receive behavioral smoking cessation counseling. STAGE II: After 6 weeks, participants from Stage I who do not quit smoking are randomized to 1 of 5 groups. GROUP III: Participants continue to receive varenicline as in Group I or NRT as in Group II for 6 weeks depending on which group they were assigned to. Participants also receive behavioral smoking cessation counseling. GROUP IV: Participants switch to a different therapy and receive varenicline as in Group I or NRT as in Group II for 6 weeks depending on which group they were assigned to. Participants also receive behavioral smoking cessation counseling. GROUP V: Participants receive a higher dose and continue to receive varenicline as in Group I or NRT as in Group II for 6 weeks depending on which group they were assigned to. Participants also receive behavioral smoking cessation counseling. GROUP VI: Participants continue to receive varenicline as in Group I or NRT as in Group II for 6 weeks depending on which group they were assigned to. Participants also receive bupropion hydrochloride (bupropion) PO daily for 6 weeks and behavioral smoking cessation counseling. GROUP VII: Participants receive varenicline as in Group I and NRT as in Group II for 6 weeks. Participants also receive behavioral smoking cessation counseling. After starting study treatment, patients are followed up at 3 and 6 months. ;

Study Design

Related Conditions & MeSH terms

  • Cigarette Smoking-Related Carcinoma
Clinical Trial Details
NCT number NCT04604509
Study type Interventional
Source M.D. Anderson Cancer Center
Contact Paul Cinciripini
Phone 713-745-3822
Email pcinciri@mdanderson.org
Status Recruiting
Phase Phase 4
Start date August 4, 2020
Completion date December 31, 2028
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06038526 - Evaluation of Canakinumab in High-Risk Former-Smokers Phase 2
Recruiting NCT05121051 - Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers Phase 2
Active, not recruiting NCT02964182 - Very Low Nicotine Content Cigarettes and E-Cigarettes in Promoting Smoking Cessation in Daily and Intermittent Cigarette Smokers N/A
Completed NCT04510077 - SmartQuit Program for Smoking Cessation N/A
Recruiting NCT06230159 - Evaluating the Impact of Synthetic Cooling Agents in Combustible Cigarettes on Smoking Perceptions and Use N/A
Completed NCT04525222 - mHealth Mood Management Tool (Actify) to Improve Population-Level Smoking Cessation Phase 1
Recruiting NCT05825001 - Evaluating the Episodic Future Thinking Intervention for Reducing Cigarette Consumption in Cigarette Smokers N/A
Completed NCT05455086 - Free-Base Nicotine or Nicotine Salt e-Liquids in Current E-Cigarette Smokers, PeloPET Study N/A
Not yet recruiting NCT06055231 - PK/PD of Vaping THC-containing Liquids vs. Smoked Cannabis Phase 1
Recruiting NCT06010355 - Culturally Tailored Educational Video to Promote Lung Cancer Screening in Vulnerable Communities N/A
Active, not recruiting NCT05236894 - Appeal of Nicotine Pouches Versus Cigarettes in the Ohio Appalachia Population Early Phase 1
Not yet recruiting NCT06213532 - CONNECTing to LungCare N/A
Recruiting NCT03856515 - Gender Differences in Switching From Smoking Regular Cigarettes to E-Cigarettes N/A
Completed NCT03480373 - Electronic Cigarette Use During Pregnancy
Not yet recruiting NCT06145763 - A Digital Smoking Cessation Intervention for Helping American Indians and Alaska Natives Quit Smoking N/A
Active, not recruiting NCT04308759 - An Innovative Conversational Agent (Quitbot) for Smoking Cessation Phase 3
Active, not recruiting NCT04972513 - Impact of E-cigarette Use on the Body
Withdrawn NCT05024955 - Evaluating Shared Decision-Making for Lung Cancer Screening Among Chinese Populations in the United States
Completed NCT05227027 - Pilot Trial of a Game Embedded in a Smartphone App for Smoking Cessation N/A
Completed NCT04502524 - Website Smoking Cessation Intervention for the Promotion of Smoking Cessation in Low-Income Veterans Phase 1